List view / Grid view
Stem cells are undifferentiated biological cells that can differentiate into specialised cells and can divide to produce more stem cells.
Explore current insights into the clinical possibilities posed by organoids and delve into short and long-term prospects for therapeutic screening and personalised regenerative medicine in this whitepaper.
Advance your neurodegeneration research with our broad antibody portfolio, ready-to-use ELISA, and cellular kits to develop new efficacious therapies.
Cell signalling through the Akt pathway controls numerous key cellular functions including proliferation, survival, and migration.
Researchers found that proteins made by stem cells that regenerate the cornea could be new targets for treating dry eye disease.
Cell proliferation assays are a cornerstone of cancer therapeutic, developmental biology, and drug safety research.
US scientists, using high-resolution imaging, debuted a new way to see cell organisation and rich variation in cell shape
Discover the Incucyte® Scratch Wound Analysis Software Module for automated image-based measurements of cell migration in vitro, using label-free analysis.
Read about the current state of the industry, challenges associated with potency assays and measuring product potency throughout the manufacturing process.
Understand how quality control assays are being implemented in monitoring the development of CAR-T cells using high-throughput technologies in this article.
The scientists found the mechanism of drug resistance depends on activation of a protein called KDM1B which controls and regulates gene expression.
This whitepaper reviews the drug discovery progress for neurodegenerative diseases, focusing on promising candidates identified using iPSC technology.
Learn how you can mobilise CD34+ haematopoietic stem cells and how they can be isolated immediately after collection.
Discover how BioIVT’s portfolio of disease state LEUKOMAX® leukopaks and PBMCs can serve as representative starting materials for autologous cell therapy research.
Discover how BioIVT’s dissociated tumour cells (DTCs) can be used for tumour-infiltrating lymphocyte (TIL) cell therapy research.
Cellistic has agreed to acquire Celyad Oncology’s Manufacturing Business Unit in Mont-Saint-Guibert, Belgium, for €6 million.
